- Home
- ACET vs YI Comparison
ACET vs YI Comparison
Compare ACET & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- YI
- Stock Information
- Founded
- ACET 1947
- YI 2010
- Country
- ACET United States
- YI China
- Employees
- ACET N/A
- YI N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- ACET Health Care
- YI Consumer Staples
- Exchange
- ACET Nasdaq
- YI Nasdaq
- Market Cap
- ACET 64.9M
- YI 70.0M
- IPO Year
- ACET N/A
- YI N/A
- Fundamental
- Price
- ACET $0.61
- YI $7.35
- Analyst Decision
- ACET Buy
- YI
- Analyst Count
- ACET 6
- YI 0
- Target Price
- ACET $6.00
- YI N/A
- AVG Volume (30 Days)
- ACET 398.4K
- YI 13.8K
- Earning Date
- ACET 08-12-2025
- YI 08-28-2025
- Dividend Yield
- ACET N/A
- YI N/A
- EPS Growth
- ACET N/A
- YI N/A
- EPS
- ACET N/A
- YI N/A
- Revenue
- ACET N/A
- YI $1,984,717,013.00
- Revenue This Year
- ACET N/A
- YI N/A
- Revenue Next Year
- ACET N/A
- YI N/A
- P/E Ratio
- ACET N/A
- YI N/A
- Revenue Growth
- ACET N/A
- YI N/A
- 52 Week Low
- ACET $0.45
- YI $4.15
- 52 Week High
- ACET $1.70
- YI $12.90
- Technical
- Relative Strength Index (RSI)
- ACET 38.76
- YI 43.52
- Support Level
- ACET $0.61
- YI $6.65
- Resistance Level
- ACET $0.69
- YI $7.70
- Average True Range (ATR)
- ACET 0.04
- YI 0.47
- MACD
- ACET -0.01
- YI -0.07
- Stochastic Oscillator
- ACET 12.80
- YI 35.78
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.